prof. dr. Claus Bachert
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 13
9000 Gent - Claus.Bachert@UGent.be
- ORCID iD
-
0000-0003-4742-1665
Show
Sort by
-
Granulocyte colony-stimulating factor : missing link for stratification of type 2-high and type 2-low chronic rhinosinusitis patients
-
- Journal Article
- A1
- open access
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
-
- Journal Article
- A1
- open access
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials
-
- Journal Article
- A1
- open access
Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers
-
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps : a randomized, placebo-controlled trial
-
- Journal Article
- A1
- open access
Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis
-
- Journal Article
- A1
- open access
The protease SplB of staphylococcus aureus targets host complement components and inhibits complement-mediated bacterial opsonophagocytosis
-
- Miscellaneous
- open access
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps : association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
-
Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies
-
- Journal Article
- A1
- open access
Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds